Xarelto Lawsuit Plaintiffs Find Support In Studies Completed On The Drug

BloodThinnerHelp.com reports on Xarelto, a blood thinner drug approved for use in 2011 by the U.S. Food and Drug Administration (FDA). Xarelto was released on the market to treat patients who may be at an increased risk of blood clots or stroke due to medical conditions such as atrial fibrillation, deep vein thrombosis, and pulmonary embolism or those who are recovering from surgeries for hip or knee replacements. The drug was hailed as a new-generation blood thinner, but it was not soon after its release that the public began to hear about links to potentially dangerous side effects of the drug.

Medical professionals Judy Hun and John Hwang began to investigate the impact of the drug on their own patients. The doctors had noticed that some of their patients suffered from a spontaneous bleeding in their eyes while taking Xarelto. They concluded after some study, that the risk of eye bleeding may be increased due to taking Xarelto.

Another study was conducted from October 1st of 2010 to March 31st of 2012 that examined a large sample of patients across the United States who had taken various blood thinner drugs such as Xarelto, Pradaxa, or warfarin. It was found that of these 46,000 patients, there was a marked increase of gastrointestinal bleeding, as much as 50 percent, when Xarelto was used versus the use of warfarin.

All of these studies have created serious concerns over the drug's alleged linkage to dangerous and spontaneous bleeding in patients. These concerns have prompted many lawsuits related to the drug, as well. Lawsuits number in excess of 2,800 cases in a federal multidistrict litigation (MDL) numbered 2592 being overseen by the Honorable Judge Eldon Fallon of the Eastern District of Louisiana, as well as a mass group tort of an additional 550 cases in Philadelphia, PA.

The Osborne firm is offering free consultations to anyone who suffered injury or hospitalization after a bleed while on Xarelto. Call (866) 425-8902 for more information about this release or the Xarelto litigation.